STAT+: Brawl over Eylea will get biosimilar trade’s consideration
Wish to keep on prime of the science and politics driving biotech immediately? Join to get our biotech e-newsletter in your inbox.
Good day! Immediately, we speak about a cool experimental enzyme remedy, observe extra patent maneuvers over Eylea, and see an ‘underdog’ startup get an enormous seed spherical to focus on a standard kidney illness.
The necessity-to-know this morning
- Soleno Therapeutics pre-announced $31-33 million in Vykat XR gross sales for the second quarter — beating consensus expectations by a large margin. The drug was permitted in late March to deal with Prader-Willi syndrome, a uncommon genetic illness that causes an insatiable want to eat. Soleno can also be elevating $200 million in a follow-on inventory sale.
- AbbVie is paying $700 million upfront to purchase licensing rights to a “trispecific antibody” therapy for most cancers developed by Ichnos World Innovation. The drug, referred to as ISB 2001, targets CD38 and BCMA protein receptors on tumor cells and the CD3 receptor on T cells. A Part 1 research in a number of myeloma is underway.
Brawl over Eylea will get biosimilar trade’s consideration
A high-stakes authorized battle between Regeneron and Amgen over the blockbuster eye drug Eylea is placing the U.S. patent system underneath a microscope — and is being carefully watched by biosimilar makers.
